MLB, NTT Unveil Groundbreaking Tech Partnership
4.9.2019 18:00:00 EEST | Business Wire | Press release
Major League Baseball (MLB) and NTT, a global technology and business solutions leader, have partnered on a multi-year technology partnership. NTT is the first Japan based information technology company to be named an official MLB partner in the United States. The announcement was made today at MLB Headquarters in New York by Baseball Commissioner Robert D. Manfred, Jr., and NTT President and Chief Executive Officer Jun Sawada.
This unique collaboration will explore and leverage the most advanced technology platforms, highlighted by NTT’s Ultra Reality Viewing (URV), to create new experiences for baseball fans. Also, as “Official MLB Fan Experience Partner for Ultra Reality Viewing” and “Title Sponsor of MLB Network Ballpark Cam,” NTT will increase its brand awareness by utilizing MLB’s various distribution platforms including digital, mobile, social, offline and television.
TECHNOLOGY PARTNERSHIP
NTT and MLB will collaborate to create an exciting new baseball fan experience using the highly advanced solution from NTT called Ultra Reality Viewing. MLB has a long-standing and successful history in building technology partnerships and emerging platforms to explore new ways for fans to consume a full baseball experience. This partnership with MLB is an excellent example of NTT's vision of using technology to help organizations and communities achieve their goals in the Smart World era and create impactful customer experiences.
INNOVATIVE FAN EXPERIENCE: ULTRA REALITY VIEWING TECHNOLOGY
Ultra Reality Viewing is NTT’s real-time super high-definition surround video synthesis technology that combines multiple 4K camera images into a super-wide image such as 12K in real-time and transmits them synchronously to remote locations. With the super high-definition surround videos which cannot be captured by general cameras, audiences can view sports content as if they were watching it live in the stadium or on the field. This is a proven solution based on NTT’s unique R&D technology, “Kirari!(*1).” It has been successfully implemented in Japan to enhance audience viewing and fan experiences with very positive results.
MLB and NTT are in the planning stages for a prototype URV experience at select upcoming games. Specific details and preview media opportunities will be announced at a later date.
“We’re excited NTT has committed to building an expanded baseball technology portfolio and we eagerly anticipate what the partnership will deliver for clubs and fans,” said Commissioner Manfred. “Sharing, and executing on, a vision to leverage advanced technologies to benefit baseball fans will serve as the foundation for how our NTT partnership will explore and experiment with unique ways to create new baseball experiences.”
"NTT is proud to partner with MLB and accelerate the future of smart sports,” said Jun Sawada, President and CEO, NTT Corporation. “Technological innovations have the potential to change sport and fan experience drastically. Based on our heritage of innovation and successful implementation experience, we will contribute to MLB’s success by creating a new fan experience with our unique Ultra Reality Viewing technology. Through this partnership, NTT aims to establish the valuable technology solution that brings Smart Sports to life.”
NTT BALLPARK CAM
NTT also becomes the title sponsor of MLB Network’s award-winning Ballpark Cam technology. Controlled from MLB Network’s studios in Secaucus, NJ, NTT Ballpark Cam is a robust network of cameras installed across all 30 MLB ballparks, allowing MLB Network to capture unique pre-game and postgame on-field footage and live on-camera interviews for each of its eight studio shows. The Emmy-nominated tech also delivers live game content to MLB Network daily for use across its live and original programming, making MLB the only U.S. pro sports league to have this type of cross-organizational asset.
(*1) For more information about NTT R&D technology “Kirari!”, please visit https://www.ntt.co.jp/activity/en/innovation/kirari/.
About MLB
Major League Baseball (MLB) is the most historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Major League Baseball is the best-attended sport in North America, and since 2004, MLB has enjoyed its best-attended seasons in the history of the game. Led by Commissioner Robert D. Manfred, Jr., MLB currently features record levels of labor peace, competitive balance and industry revenues, as well as the most comprehensive drug-testing program in American professional sports. MLB remains committed to making an impact in the communities of the U.S., Canada and throughout the world, perpetuating the sport’s larger role in society and permeating every facet of baseball’s business, marketing and community relations endeavors. With the continued success of MLB Network and MLB digital platforms, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. For more information on Major League Baseball, visit www.MLB.com.
About NTT
NTT is a global technology and business solutions provider. We help clients grow their business and improve their competitive market position by delivering fully integrated services, including global networks, cybersecurity, managed IT and applications, cloud and datacenter services combined with business consulting and deep industry expertise. As a top-five global technology and business services provider, NTT works with over 80 of the Global Fortune 100 companies and many thousands of other clients and communities to achieve their goals and contribute to a sustainable future. For more information on NTT, visit www.global.ntt.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190904005624/en/
Contact information
MLB Communications
(212) 931-7878, MLBPressBox.com, @MLB_PR
NTT
Public Relations
ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom